Ajanta Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Ajanta Pharma from all sources in a single place.

Ajanta Pharma Ltd.

10 Dec 2025

2659.80

0.32%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 10, 2025 for Aayush Agrawal, trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

09 Dec 2025, 08:45PM

2659.80

0.32%

Ajanta Pharma sets aside 1K crore for acquisitions to plug therapy gaps

Business Standard

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Ajanta Pharma Ltd. has an average target of 2939.17 from 6 brokers.

Ajanta Pharma Ltd.

29 Nov 2025

2659.80

0.32%

Ajanta Pharma: Growth continues but valuations drift higher

Business Line

Ajanta Pharma is placed well in its markets, but margin headwinds have to be monitored

Ajanta Pharma Ltd. has an average target of 2939.17 from 6 brokers.

Ajanta Pharma Ltd.

28 Nov 2025

2659.80

0.32%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 26, 2025 for Aayush Agrawal, trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

13 Nov 2025

2659.80

0.32%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 13, 2025 for Ravi Agrawal, trustee Ravi Agrawal Trust

pdf

Ajanta Pharma Ltd.

06 Nov 2025

2659.80

0.32%

Earnings Call

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Pls find enclosed Written Transcript of Earnings Call

pdf

Ajanta Pharma Ltd.

04 Nov 2025

2659.80

0.32%

Company Update

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

PFA Newspaper Publication of Financial Results

pdf

Ajanta Pharma Ltd.

04 Nov 2025

2659.80

0.32%

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

Business Standard

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Ajanta Pharma Ltd. has an average target of 2939.17 from 6 brokers.

Ajanta Pharma shares gain 3% on Q2FY26 results, dividend update; details

Business Standard | 03 Nov 2025 1 more

Ajanta Pharma Ltd.

04 Nov 2025

2659.80

0.32%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Q2FY26- Momentum driven by US and India Business - Revenues grew ~14% YoY to 1354 crore driven by US and India branded business which grew ~48% / ~12% to 344 crore and 432 crore, respectively. Other branded businesses such as Asia and Africa witnessed the growth of 5% / 4% (on higher base) to 310 crore and 221 crore, respectively. On the operational front, EBITDA grew 5.4% YoY to ~328 crore (excluding forex losses of 41 crore, 9 % growth to ~369 crore) with margins at 24.2%...